“Sales in Q2 2026 were USD 259 million, representing 11% reported growth and 6% organic growth. Strong double-digit Prosthetics & Neuro Orthotics growth in Q2, supported by excellent execution, robust volume growth in EMEA and APAC, and successful new product launches. Bracing & Supports delivered moderate growth in the quarter, while Patient Care declined.

The EBITDA margin was strong at 22% in Q2 2026, up 1%-point from Q2 2025, reflecting solid sales contribution from Prosthetics & Neuro Orthotics, continued cost discipline, and US tariff refunds."

Embla will host a conference call on July 21, 2026 at 09:00 CET / 7:00 GMT / 3:00 EST.

To actively participate in the telephone conference, please use the dial-in details provided below:
DK: +45 78 76 84 90
UK: +44 20 3769 6819
US: +1 646 787 0157
Participant access code: 274982

A webcast can be followed by clicking the link below:

Embla Medical Q2 2026 Webcast

Related documents:

• Company Announcement (PDF)
• Investor Presentation (PDF)